MarkBJuckettMDMHCM

PubMed

• Biobehavioral mechanisms underlying symptoms in cancer patients with chronic graft-versus-host disease.
  Jenna L Hansen, Meredith E Rumble, Christopher L Coe, Mark B Juckett, Mikayla A Foster
  Brain, Behavior, and Immunity. 2025-01-01
• N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase...
  Aimee Merino, Claudio C Brunstein, Ryan Shanley, Faridullah Rashid, Rose Wangen
  Transplantation and Cellular Therapy. 2024-12-01
• Correction: Psychological and physical function in allogeneic hematopoietic cell transplant survivors with chronic graft-versus-host disease.
  Jenna L Hansen, Mark B Juckett, Mikayla A Foster, Meredith E Rumble, Keayra E Morris
  Journal of Cancer Survivorship. 2024-12-01

Journal Articles

• What is the value of the computer to the physician?  
  MB Juckett, JS Spratt, Journal of Surgical Oncology 34:1-5
• Iron chelation impairs clonogenic survival and enhances gamma radiation induced injury of endothelial cells.  
  MB Juckett, A Zheng, J Shadley, Radiation Research 149: 330-337
• Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction.  
  CJ Link, RK Burt, AE Traynor, WR Drobyski, T Seregina, JP Levy, L Gordon, ST Rosen, WH Burns, B Camitta, J Casper, M Horowitz, M Juckett, C Lawton, D Margolis, D Pietr..., Human Gene Therapy 9(1):115-34
• Heme and endothelium: Effects of Nitric Oxide on Catalytic Iron, and Heme Degradation by Heme Oxygenase.  
  MB Juckett, Y Zheng, H Yuan, T Pastor, W Antholine, M Weber, GM Vercellotti, Journal of Biological Chemistry 273(36):23388-23397
• Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial.  
  Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JA, Juckett MB, Moulder JE, Int J Radiat Oncol Biol Phys
• Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.  
  Vanderhoek M, Juckett MB, Perlman SB, Nickles RJ, Jeraj R, Leuk Res
• Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).  
  Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, Laplant B, Laumann K, Erlichman C, Dipersio J, Ann Hematol
• American Society of Blood and Marrow Transplantation Guidelines for Training in Hematopoietic Progenitor Cell Transplantation.  
  Khan S, Juckett MB, Komanduri KV, Krishnan A, Burns LJ, Biol Blood Marrow Transplant
• Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refrac...  
  Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S. Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M, Invest New Drugs
• The Match is Back.  
  Juckett MB, The Hematologist
• Learning in Las Vegas: The ASH State-of-the-Art Symposium.  
  Juckett MB, The Hematologist
• Join now to see all

Abstracts/Posters

• Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults.
  WH Navarro, MA Agovi, B Logan, A Bacigalupo, KK Ballen, BJ. Bolwell, H Frangoul, V Gupta, T Hahn, M Juckett, HM. Lazarus, MR. Litzow, J Liesveld, J Moreb, D Marks, PL..., Blood (ASH Annual Meeting Abstracts)
• Generation of Epstein Barr Virus-Specific T cell lines from Patient Blood Post Bone Marrow and Solid Organ Transplantation.
  CA Keever-Taylor, RJ Orentas, M Juckett, J Casper, D Margolis, B Davies, S Konings, P Rivers, and W Burns, International Society for Hematotherapy and Graft Engineering Meeting., San Diego, CA
• Anti-CD20 Monoclonal antibody treatment for post-transplant B-cell lymphoma.
  N Siddiqi, M Juckett, R Orentas, B Bresnahan, S Hariharan, Joint Meeting of the American Society of Transplant Surgeons and the American Society of ...., Chicago, IL
• Loss of Renal Function following Bone Marrow Transplantation: An analysis of Angiotensin Converting Enzyme D/I Polymorphism and other Clinical Risk Factors.
  MB Juckett, EP Cohen, CA Keever-Taylor, Y Zheng, CA Lawton, JE Moulder, J Klein, Blood 96 (Suppl 1): 394a
• High Tumor Load in Patients with Follicular Lymphoma (FL) Post Allogeneic Bone Marrow Transplantation (Allo-BMT) Correlates with Relapse of Disease.
  C Chang, M Juckett, B Schur, CA Keever-Taylor, Blood 98 (Suppl 1): 392a
• High Dose Thiotepa and Etoposide: Long Term Experience with a Novel Conditioning Regimen for Autologous BM/PBPC Transplant in 65 NHL Patients.
  AM Garry McCoy, EP Smith, M Atkinson, B Baranski, BS Kahl, MB Juckett, TL Mitchell, R Gangnon, WL Longo, Blood 98 (Suppl 2): abst 5350
• A Phase 2 Consortium (P2C) Trial of R115777 (Zarnestra) in Myelofibrosis with Myeloid Metaplasia: Interim Analysis of 18 Patients.
  Ruben A. Mesa, John K. Camoriano, Susan M. Geyer, Scott H. Kaufmann, Charles Erlichman, Mark Juckett, Ayalew Tefferi, Blood 102 (11): Abst 3428, 2003
• University of Wisconsin experience treating adult ALL with the BFM regimen.
  S. C. Medlin, B. Kahl, W. Longo, E. Williams, J. Lionberger, J. Kim, K. Kim, M. Juckett, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S
• Development of a Competency-based Curriculum for a Hematology Fellowship.
  MB Juckett, C Gjerde, Medical Education Day, University of Wisconsin Medical School
• Thalidomide maintenance following high-dose melphalan with autologous stem cell transplant for myeloma.
  JE Chang, MB Juckett, BS Kahl, TL Mitchell, RE Gangnon, NS Callander, WL Longo, Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 5455
• Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma.
  M Raschko, S Markovina, S Miyamoto, W Longo, E Williams, T McFarland, J Werndli, E Wagner, M Juckett, N Callander, Blood (ASH Annual Meeting Abstracts)
• A Comparitic Analysis of Transplant Outcomes in Patients receiving Unrelated versus Highly HLA-disparate Haploidentical Family Member Donor Marrow Grafts for the treat...
  W. R. Drobyski, J. Klein, D. Pietryga, N. Flomenberg, C. Kabler-Babbitt, D. H. Vesole, D. A. Margolis, C. A. Keever-Taylor, M. Horowitz, M. Juckett, J. D. Rizzo, D. Ba..., Blood 94 (Suppl 1): 564a
• A Pilot Study for Using 3’-Deoxy-3’-[18f]Fluorothymidine Positron Emission Tomography ([18F]FLT PET/CT) Imaging for Early Assessment of Response to Induction Chemothe...
  MB. Juckett, M Vanderhoek, S Perlman, R Nickles and R Jeraj, Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 2550
• The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).
  NS Callander, MD, S Markovina, BA, MB. Juckett, MD, E Wagner, MA, J Koalas, W Longo, EC. Williams, MD, PhD, K Kim PhD, J Werndli, BSc, MSc, and S Miyamoto, PhD, Blood (ASH Annual Meeting Abstracts) 2009 114: Abstract 3885
• Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?
  J Horan, MD, MPH, BR. Logan, PhD, MA. Agovi, MPH, HM Lazarus, MD, A Bacigalupo, MD, K Ballen, R Martino, MB. Juckett, MD, HJ. Khoury, MD, C Bredeson, MD, V Gupta, FO. ..., Blood (ASH Annual Meeting Abstracts) 2009 114: Abstract 649
• Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia ...
  Thomas Prebet, Steven D. Gore, Zhuoxin Sun, Peter L. Greenberg, Mark Juckett, Lisa Malick, Mitchell R Smith, Elisabeth Paietta, Magdalena Czader, Janice Gabrilove, Har..., Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 601
• WiTALK: Improving the Way We Communicate with Patients.
  Toby Campbell, Kunal Karmali, Amy Smith, Sam Lubner, Mark Juckett, Ryan Mattison, Bennett Vogelman, the Association of Program Directors in Internal Medicine (APDIM) Spring Meeting, Las Vegas, NV
• Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).
  A. F. Cashen, M. Juckett, A. Jumonville, M. R. Litzow, P. J. Flynn, J. R. Eckardt, B. LaPlant, K. M. Laumann, C. Erlichman, and J. F. DiPersio, ASCO MEETING ABSTRACTS
• Phase II study of AZD2171 for the treatment of patients with acute myelogenous leukemia.
  M. Juckett, B. LaPlant, PJ Flynn, A. Jumonville, A. Moreno-Aspitia, C. Erlichman, the ASCO annual meeting 2011. J. Clin. Oncol. 29:2011 (suppl; abstr 6574)
• Phase 2 Consortium (P2C)Phase II study of AZD2171 for the treatment of patients with Myelodysplastic syndromes.
  Shannon Eileen O'Mahar, Alcee Jumonville, Patrick J. Flynn, Alvaro Moreno-Aspitia, Charles Erlichman, Betsy LaPlant, Mark Juckett, ASCO MEETING ABSTRACTS May 30, 2012:6570
• Immune responses contribute to depression, fatigue, and pain in blood and marrow transplant recipients Biology of Blood and Marrow Transplantation.
  E.S. Costanzo, M.B. Juckett, A.M. Nelson, A.A. Erdmann, P.J. Rathouz, P. Hematti, C.L. Coe, Volume 18, Issue 2, Supplement, Page S282
• Nitric oxide inhibits the catabolism of cellular heme.
  M Juckett, Y Zheng, H Yuan, T Pastor, W Antholine, Proc. Annual Meeting of the Oxygen Society
• Ferritin protects endothelial cells from oxidized low-density lipoprotein mediated cytotoxicity.
  MB Juckett, J Balla, G Balla, B Burke, HS Jacob, GM Vercellotti, Clin Res 41(2):162A
• Endothelial ferritin induction by iron is inhibited by nitric oxide generators.
  MB Juckett, J Balla, ML Weber, JM Peloquin, HS Jacob, GM Vercellotti, Blood 82(10, Suppl 1): 1993
• Nitric oxide as an antioxidant: role in LDL oxidation, endothelial cell injury, and iron availability.
  MB Juckett, J Murar, ML Weber, HS Jacob, GM Vercellotti, Clin Res 42(3):360A
• Join now to see all

Lectures

• Adult and Pediatric BMT 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Introduction to Practice-Improvement Modules. 
  American Society of Blood and Marrow Transplantation
• How to Negotiate ASH. 
  Trainee Reception, American Society of Hematology Annual Meeting
• Monoclonal Antibodies of Potential Use in Stem Cell Transplantation. 
  Tandem Bone Marrow Transplantation Meeting, Keystone CO
• Heme and the Endothelium: Effect of Nitric Oxide on Catalytic iron and Ferritin. 
  Gordon Research Conference: Oxygen Radicals, Ventura CA
• Join now to see all